Contact Us
Drug Search Results
More Filters [+]

KH-658

Alternative Names: KH-658, KH 658, KH658
Latest Update: 2024-06-13
Latest Update Note: Clinical Trial Update

Product Description

KH658 is a adeno-associated virus (AAV) vector-based gene therapy for suprachoroidal space injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06458595?term=kh658&draw=2&rank=1)

Mechanisms of Action: Gene Therapy

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: Ophthalmic,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chengdu Hongji Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KH-658

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
KH658-40101

P2

Not yet recruiting

Macular Degeneration

2026-03-31

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions